56.26
전일 마감가:
$55.15
열려 있는:
$55.61
하루 거래량:
681.18K
Relative Volume:
0.80
시가총액:
$3.49B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
21.47
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
+1.88%
1개월 성능:
+1.02%
6개월 성능:
+48.09%
1년 성능:
+39.67%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
56.26 | 3.42B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-17 | 개시 | Citigroup | Buy |
2024-12-06 | 개시 | BMO Capital Markets | Outperform |
2024-12-06 | 개시 | Goldman | Neutral |
2024-11-05 | 개시 | Wedbush | Outperform |
2024-09-24 | 개시 | TD Cowen | Buy |
2024-09-09 | 개시 | Truist | Buy |
2023-10-30 | 개시 | CapitalOne | Overweight |
2023-05-25 | 재개 | Jefferies | Buy |
2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
2022-02-11 | 개시 | BTIG Research | Buy |
2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
2021-05-24 | 개시 | Northland Capital | Outperform |
2021-01-06 | 개시 | JP Morgan | Overweight |
2020-12-16 | 개시 | Piper Sandler | Overweight |
2020-09-18 | 재확인 | H.C. Wainwright | Buy |
2020-07-15 | 개시 | Jefferies | Buy |
2020-05-18 | 재확인 | H.C. Wainwright | Buy |
2019-07-08 | 개시 | H.C. Wainwright | Buy |
2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
2018-12-06 | 개시 | Nomura | Buy |
2018-01-29 | 개시 | Stifel | Buy |
2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com India
What is the dividend policy of Protagonist Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - jammulinksnews.com
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - jammulinksnews.com
What institutional investors are buying Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - jammulinksnews.com
Is Protagonist Therapeutics Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayShort Squeeze Radar - metal.it
Does Protagonist Therapeutics Inc. stock pay reliable dividendsFree Consultation - metal.it
Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis - MSN
Protagonist Therapeutics Inc. Stock Analysis and ForecastExponentially increasing returns - PrintWeekIndia
What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News
CEO’s Major Stock Sale Shakes Up Protagonist Therapeutics! - TipRanks
Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India
Protagonist Therapeutics CEO Patel sells $2.88 million in shares - Investing.com
What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional
Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal
Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com
Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):